Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy

Abstract

Assessing nearly 14,000 women from a contemporary United States database, this is the largest known study examining the relationship between response to NC and molecular subtype. Women with luminal A disease are the least likely to undergo pCR, with the highest rates in Her2 disease. Degree of response is associated with OS, especially in luminal B, Her2, and TN patients. Despite the comparatively higher likelihood of achieving pCR in TN cases, this subgroup may still experience a survival detriment, which has implications for an ongoing national randomized trial.

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36480 cases. 

“…Consistent with our study, other studies have con rmed that patients with TNBC have a better prognosis after achieving pCR following NACT [7,29]. Although patients who received NACT may have advanced disease,achieving pCR following NACT signi cantly improved survival.…”

Stereotactic radiosurgery for brain metastases from newly diagnosed small cell lung cancer: practice patterns and outcomes

“…Our study had several limitations inherent to studies from large databases [22][23][24][25][26][27][28][29][30][31]. First, there is a lack of disease-specific information in the NCDB, including a number of intracranial metastases, size, and location.…”

Prognostic utility of atypical mitoses in patients with breast cancer: A comparative study with Ki67 and phosphohistone H3

“…Luminal A type referred to ER + /PgR + /HER2 − with low histological grade. As luminal B has multiple definitions, we encompassed cases of ER + /PgR + /HER2 − with intermediate/high histological grade, or ER + /PgR + /HER2 + with any histological grade as luminal B, as described elsewhere . HER2 type corresponded to ER − /PgR − /HER2 + , and triple‐negative phenotype (TN) was ER − /PgR − /HER2 − .…”